Compare AIV & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | ALT |
|---|---|---|
| Founded | 1975 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.9M | 421.5M |
| IPO Year | 1996 | 2005 |
| Metric | AIV | ALT |
|---|---|---|
| Price | $2.97 | $2.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $17.67 |
| AVG Volume (30 Days) | 1.7M | ★ 3.4M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 87.41% | N/A |
| EPS Growth | ★ 616.00 | 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $138,486,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $2.85 | $2.56 |
| 52 Week High | $8.87 | $6.44 |
| Indicator | AIV | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 25.30 | 48.08 |
| Support Level | $2.85 | $2.72 |
| Resistance Level | $4.30 | $3.20 |
| Average True Range (ATR) | 0.06 | 0.12 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 60.71 | 49.45 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.